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Abstract
Ventilator-associated pneumonia is a severe complication among patients undergoing cardiac
surgery. Although hospital-acquired bacterial pathogens, often multidrug resistant, are the most
frequent cause, non-bacterial atypical and opportunistic agents traditionally associated with
immunocompromise are increasingly recognized. We describe ventilator-associated pneumonia
due to Pneumocystis jirovecii in the absence of traditional risk factors for Pneumocystis
pneumonia in a patient after cardiac surgery.
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Introduction
Ventilator-associated pneumonia (VAP) is an important condition, given its morbidity, mortality
and associated health care costs[1]. Common causes of VAP include multidrug-resistant bacteria
such as Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and
methicillin-resistant Staphylococcus aureus[2], however atypical and opportunistic pathogens,
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including Chlamydia pneumoniae and Mycoplasma pneumoniae, Candida albicans and other
fungi, are increasingly recognized in patients who have undergone cardiothoracic surgery[3,4]. We
describe a patient with VAP caused by another opportunistic organism, Pneumocystis jirovecii, in
the absence of traditional risk factors for Pneumocystis pneumonia (PCP).
Case report
A 64-year-old woman with rheumatic mitral valve disease presented with progressive impairment
of functional capacity resulting in heart failure (New York Heart Association Functional Class III).
Her past medical history was unremarkable and the patient was not taking corticosteroids or
other immunosuppressive therapy. On examination, the patient had a normal nutritional status
(body mass index¼19.5kg/m2), there was no lymphadenopathy or organomegaly, and no
stigmata of Cushing syndrome were evident. Echocardiography showed moderate to severe
mitral regurgitation, mild mitral stenosis, a left ventricular ejection fraction of 40%, and severe
tricuspid regurgitation. Coronary angiography and a high-resolution chest computed tomography
(CT) scan were normal. A human immunodeficiency virus (HIV) test (ELISA combined HIV-1 and
HIV-2 antibody plus HIV-1 p24 antigen) was negative, and blood glucose and serum albumin
levels, neutrophil and total lymphocyte counts, and biochemical tests of renal, liver, and bone
function were normal.
The patient underwent mitral valve replacement (Carpentier Edwards PERIMOUNT; Edwards
Lifesciences, Irvine, CA) and tricuspid valve repair surgery. During the immediate (2–8h)
postoperative period she developed cardiovascular instability requiring vasopressor support
and mechanical ventilation. Echocardiography revealed moderate biventricular systolic dysfunc-
tion without an abnormal mitral gradient. Vasopressor drugs were withdrawn, loop diuretics were
started, and weaning from mechanical ventilation was achieved by 24h postoperatively.
Despite a negative fluid balance and intermittent non-invasive ventilatory bilevel positive airway
pressure, the patient deteriorated, with increased work of breathing, hypoxemia (Pao2:Fio2 ratio
5150), and radiographic evidence of new infiltrates, and was re-intubated on the fifth
postoperative day. The acute lung injury was ascribed to VAP; inflammatory markers showed
white blood cells (WBC)¼18,200 cells/ml, C-reactive protein¼300mg/l (normal 55mg/l) and
procalcitonin¼5.9ng/ml (normal50.15ng/ml). After collecting urine, peripheral and central line
blood samples for culture, and an endotracheal aspirate for quantitative cultures, empiric
antibiotic therapy was initiated with piperacillin/tazobactam with vancomycin.
A CT scan of the chest, done 6h before re-intubation showed diffuse bilateral alveolar
infiltrates and ground-glass opacities with sparing of the basal segments of the lower left lobe.
The patient deteriorated, developing cardiovascular failure requiring vasopressor and inotropic
support. Microbiological studies were negative, and so vancomycin was stopped and piperacillin/
tazobactam was continued. The patient stabilized hemodynamically, and inflammatory markers
improved (WBC¼13,400 cells/ml, C-reactive protein¼74mg/l, and procalcitonin¼0.88ng/ml);
serum amylase and bilirubin levels were normal.
By the eighth day of mechanical ventilation, the respiratory failure had worsened with
development of multiple organ dysfunction (acute renal failure and thrombocytopenia; serum
bilirubin and amylase levels remained normal). In addition, inflammatory markers had
deteriorated together with the reappearance of cardiovascular instability. On day 13 of
mechanical ventilation, a thoracic CT scan showed diffuse bilateral alveolar infiltrates with
dilatation and distortion of bronchial structures. New alveolar infiltrates were seen in the left lung
(Fig. 1) and bronchoscopic alveolar lavage (BAL) via the endotracheal tube was done.
Postbronchoscopy VAP treatment was escalated, with re-initiation of vancomycin and empiric
administration of imipenem, fluconazole and amikacin. Analysis of BAL fluid for detection of
bacterial pathogens (by microscopy and culture) was negative, as were molecular detection tests
for influenza A and B and respiratory syncytial virus. BAL fluid was negative for hemosiderin-
laden macrophages, excluding occult alveolar haemorrhage as a cause.
Despite empiric antibiotics, and inotropic, vasopressor and ventilator support, the patient
deteriorated and died on the 20th postoperative day. The family refused permission for necropsy.
After the patient’s death, analysis of stored BAL fluid showed the presence of P. jirovecii in single
forms or typical clusters (one every ten fields at 20 magnification), demonstrated by Grocott-
Gomori methenamine silver stain (Fig. 2a), and by detection of Pneumocystis-specific DNA using a
single round polymerase chain reaction (PCR) using the oligonucleotide primers, pAZ102E and
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pAZ102H, designed to detect the gene encoding the mitochondrial large subunit ribosomal
ribonucleic acid (LSU mt rRNA) gene of Pneumocystis spp.[5] (Fig. 2b).
Discussion
The patient described here meets the diagnostic criteria for VAP[1]. The clinical and radiological
progression while ventilated, the repeatedly negative results of bacterial culture of blood and
endotracheal samples and demonstration of P. jirovecii in BAL fluid by histochemical staining and
single round PCR strongly support the inference that Pneumocystis had a pathological role in this
case. Cardiac and non-infectious pulmonary and extrapulmonary causes of ventilator-associated
pulmonary infiltrates were excluded.
PCP as the cause of VAP in this patient probably represents progression from asymptomatic
colonization to clinical disease in the context of a critically ill immunocompromised patient after
cardiac surgery[6]. Cardiac surgery may induce immunosuppression; likely mechanisms include
activation of anti-inflammatory cytokines, surgical trauma, reperfusion injury, and the effect of
cardiopulmonary bypass[7,8].
The origin of P. jirovecii in this patient is difficult to ascertain. Person-to-person transmission of
P. jirovecii has been described in several inpatient and outpatient hospital clinical settings and
person-to-person transmission has been suggested among immunocompetent contacts of patients
Fig. 2. (a) Bronchoscopic alveolar lavage specimen. Cluster of P. jirovecii cystic forms (centre). Grocott-Gomori methenamine
silver stain (magnification 40). (b) Products of DNA amplification displayed on an ethidium gel, using the Pneumocystis-
specific oligonucleotide primers (pAZ102E and pAZ102H) applied to DNA extracted from BAL fluid from the patient. Key: L,
1 kb molecular weight markers (sizes shown to the left of the column); IC, human -globin as internal control; NC, negative
control (with no added DNA template); Pt, patient; blank, one-fifth dilution of patient sample; PC, two P. jirovecii DNA-
positive controls. The Pneumocystis-specific amplification product¼346 base pairs.
Fig. 1. CT thorax performed after 13 days of mechanical ventilation, showing diffuse bilateral alveolar infiltrates with areas
of ground-glass opacity, and dilatation and distortion of bronchial structures.
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with PCP[9,10]. However, the slow growth rate of Pneumocystis makes it unlikely that this case
represents a nosocomial infection acquired from another patient during her brief hospitaliza-
tion[11]. In addition, no other patients with PCP were contemporaneously diagnosed in the
hospital. Asymptomatic infection with P. jirovecii is common in the general population and the
role of these persons as an infective reservoir is possible[12,13].
Pneumocystis jirovecii has previously been described as a cause of VAP[2,4,14]. Among 35 cases of
VAP occurring in 2167 patients after cardiac surgery, fungi accounted for 15 episodes; of these
two were due to P. jirovecii[2]. Puzio et al.[4] described 27 patients from a cohort of 5026 who had
undergone cardiac surgery and who developed prolonged respiratory failure requiring mechanical
ventilation in whom atypical or opportunistic pathogens were identified. P. jirovecii was identified
in 17/27 patients (together with C. pneumoniae in three patients (one of whom also had M.
pneumonia)). Another study described VAP caused by P. jirovecii in five elderly patients (age 71–
93 years)[14]. Although our patient shares a history of cardiac surgery with these studies, by
contrast our patient had no underlying medical condition, and was not taking corticosteroids or
other immune suppressive drugs. In the study by Puzio et al.[4], the significance of identifying P.
jirovecii in tracheal aspirates is uncertain, as 7/27 patients had a normal chest radiograph, 10 had
underlying chronic lung disease and 4 were immunosuppressed because they had undergone
heart or lung transplantation. All five elderly patients described by Yu and Sun[14] had cancer or
were receiving corticosteroid therapy.
P. jirovecii as a cause of VAP is extremely rare, and thus it should be considered in cases with
highly suggestive thoracic CT imaging and/or negative bacterial cultures of BAL fluid.
Teaching points
 This case highlights the emerging importance of unusual pathogens, including P. jirovecii, in
the pathogenesis of VAP in non-neutropenic, non-lymphopenic critically unwell, HIV-
uninfected patients undergoing cardiac surgery.
 Clinicians should be alert to the potential for atypical and opportunistic organisms to cause
VAP in the postoperative period, especially among patients with prolonged respiratory
compromise and a need for mechanical ventilation.
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